A new trading day began on November 20, 2023, with Ginkgo Bioworks Holdings Inc (NYSE: DNA) stock priced at $1.51, up 0.66% from the previous day of trading. During the day, the shares moved up to $1.58 and dropped to $1.48 before settling in for the closing price of $1.52. DNA’s price has ranged from $1.12 to $2.55 over the past 52 weeks.
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 180.81%. Meanwhile, its annual earnings per share averaged 66.70%. With a float of $1.30 billion, this company’s outstanding shares have now reached $1.34 billion.
The extent of productivity of a business whose workforce counts for 1292 workers is very important to gauge. In terms of profitability, gross margin is +44.35, operating margin of -452.56, and the pretax margin is -444.08.
Ginkgo Bioworks Holdings Inc (DNA) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Ginkgo Bioworks Holdings Inc is 33.46%, while institutional ownership is 58.83%. The most recent insider transaction that took place on Nov 16, was worth 145,200. In this transaction an insider of this company sold 100,000 shares at a rate of $1.45, taking the stock ownership to the 5,094,680 shares. Before that another transaction happened on Nov 16, when Company’s 10% Owner sold 37,650 for $1.45, making the entire transaction worth $54,705. This insider now owns 12,562,794 shares in total.
Ginkgo Bioworks Holdings Inc (DNA) Latest Financial update
In its latest quarterly report, released on 9/29/2023, the company reported earnings of -$0.16 per share, which was $0.1 lower than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). This company achieved a net margin of -440.63 while generating a return on equity of -129.87. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.08 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 66.70% per share during the next fiscal year.
Ginkgo Bioworks Holdings Inc (NYSE: DNA) Trading Performance Indicators
Here are Ginkgo Bioworks Holdings Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 6.78. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 9.50.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.45, a number that is poised to hit -0.10 in the next quarter and is forecasted to reach -0.28 in one year’s time.
Technical Analysis of Ginkgo Bioworks Holdings Inc (DNA)
The latest stats from [Ginkgo Bioworks Holdings Inc, DNA] show that its last 5-days average volume of 20.01 million was inferior to 20.85 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 69.98%. Additionally, its Average True Range was 0.13.
During the past 100 days, Ginkgo Bioworks Holdings Inc’s (DNA) raw stochastic average was set at 23.30%, which indicates a significant decrease from 64.46% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 120.13% in the past 14 days, which was higher than the 93.45% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.6272, while its 200-day Moving Average is $1.6523. Now, the first resistance to watch is $1.5800. This is followed by the second major resistance level at $1.6300. The third major resistance level sits at $1.6800. If the price goes on to break the first support level at $1.4800, it is likely to go to the next support level at $1.4300. The third support level lies at $1.3800 if the price breaches the second support level.
Ginkgo Bioworks Holdings Inc (NYSE: DNA) Key Stats
With a market capitalization of 2.99 billion, the company has a total of 2,098,853K Shares Outstanding. Currently, annual sales are 477,710 K while annual income is -2,105 M. The company’s previous quarter sales were 55,430 K while its latest quarter income was -302,890 K.